The allogeneic advantage: engineering NK cells for durable, scalable cell therapies

Natural killer (NK) cell therapies are rapidly advancing toward clinical maturity, offering new opportunities for cancer treatments. As the field evolves beyond traditional approaches, more sophisticated genetic engineering has become essential for creating durable, scabale, and effective therapies.

This white paper explores how base editing technology enables NK cell engineering of complex, multiplex modifications without the cellular stress and manufacturing challenges associated with traditional CRISPR approaches.

Inside this white paper:

• The advantages of multiplex engineering strategies for NK cell therapy development
• Why traditional CRISPR methods limit NK cell engineering and how base editing can overcome these biological constraints
• How Revvity's Pin-point™ base editing platform helps preserve cell viability while allowing sophisticated genetic modifications across multiple loci
• Strategic partnerships and licensing opportunities to help accelerate your therapeutic development timeline

Download this white paper to learn how to transform your NK cell engineering approach and unlock new therapeutic possibilities.

The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.